TNFSF4 and neoplasm: Jiang et al. reported that oncolytic adenovirus combined with the immune costimulator OX40 ligand (OX40L, TNFSF4) could enable immune cells to accurately recognise tumour-associated antigens and reduce the adverse effects caused by the activation of irrelevant T cells [21].